| Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine SJ Goldie, M Kohli, D Grima, MC Weinstein, TC Wright, FX Bosch, ... Journal of the National Cancer Institute 96 (8), 604-615, 2004 | 753 | 2004 |
| A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV‐16/18 vaccine SJ Goldie, D Grima, M Kohli, TC Wright, M Weinstein, E Franco International Journal of cancer 106 (6), 896-904, 2003 | 259 | 2003 |
| A Microsoft-Excel-based tool for running and critically appraising network meta-analyses—an overview and application of NetMetaXL S Brown, B Hutton, T Clifford, D Coyle, D Grima, G Wells, C Cameron Systematic reviews 3, 1-11, 2014 | 228 | 2014 |
| Cost and health related quality of life consequences of multiple sclerosis DT Grima, GW Torrance, G Francis, G Rice, AJ Rosner, L Lafortune Multiple Sclerosis Journal 6 (2), 91-98, 2000 | 208 | 2000 |
| Cost‐effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States DA Marshall, SH Kleinman, JB Wong, JP AuBuchon, DT Grima, NA Kulin, ... Vox sanguinis 86 (1), 28-40, 2004 | 181 | 2004 |
| Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis CA Hutchison, N Heyne, P Airia, R Schindler, D Zickler, M Cook, ... Nephrology Dialysis Transplantation 27 (10), 3823-3828, 2012 | 174 | 2012 |
| Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions ANA Tosteson, B Jönsson, DT Grima, BJ O’Brien, DM Black, JD Adachi Osteoporosis international 12, 849-857, 2001 | 112 | 2001 |
| Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada DT Grima, MF Thompson, L Sauriol Pharmacoeconomics 25, 253-266, 2007 | 66 | 2007 |
| Cost-effectiveness analysis of therapies for chronic kidney disease patients on dialysis: a case for excluding dialysis costs DT Grima, LM Bernard, ES Dunn, PA McFarlane, DC Mendelssohn Pharmacoeconomics 30, 981-989, 2012 | 51 | 2012 |
| Outcomes and costs of autologous stem cell mobilization with chemotherapy plus G-CSF vs G-CSF alone AD Sung, DT Grima, LM Bernard, S Brown, G Carrum, L Holmberg, ... Bone marrow transplantation 48 (11), 1444-1449, 2013 | 49 | 2013 |
| Cost effectiveness of multi-therapy treatment strategies in the prevention of vertebral fractures in postmenopausal women with osteoporosis AJ Rosner, DT Grima, GW Torrance, C Bradley, JD Adachi, RJ Sebaldt, ... Pharmacoeconomics 14, 559-573, 1998 | 45 | 1998 |
| Adverse events, bone mineral density and discontinuation associated with generic alendronate among postmenopausal women previously tolerant of brand alendronate: a … DT Grima, A Papaioannou, P Airia, G Ioannidis, JD Adachi BMC Musculoskeletal Disorders 11 (1), 68, 2010 | 42 | 2010 |
| Clinical and economic impacts of latanoprost 0.005% in first-line treatment of open-angle glaucoma and ocular hypertension in France LM Bernard, R Althin, R Dhawan, DT Grima, A Lam, S Aballea European journal of ophthalmology 13 (4_suppl), 30-43, 2003 | 37 | 2003 |
| Modelled cost-effectiveness of high cut-off haemodialysis compared to standard haemodialysis in the management of myeloma kidney DT Grima, P Airia, C Attard, CA Hutchison Current medical research and opinion 27 (2), 383-391, 2011 | 36 | 2011 |
| Lack of increased colonization with vancomycin-resistant enterococci during preferential use of vancomycin for treatment during an outbreak of healthcare-associated Clostridium … M Miller, L Bernard, M Thompson, D Grima, J Pepin Infection Control & Hospital Epidemiology 31 (7), 710-715, 2010 | 34 | 2010 |
| Cost–effectiveness of combinatorial pharmacogenomic testing for depression from the Canadian public payer perspective JA Tanner, PE Davies, CC Overall, D Grima, J Nam, BM Dechairo Pharmacogenomics 21 (8), 521-531, 2020 | 29 | 2020 |
| Cost-effectiveness of oxaliplatin in the adjuvant treatment of colon cancer in Canada CL Attard, JA Maroun, K Alloul, DT Grima, LM Bernard Current Oncology 17 (1), 17-24, 2010 | 28 | 2010 |
| Cost-effectiveness of ticagrelor versus clopidogrel in patients with acute coronary syndromes in Canada DT Grima, ST Brown, L Kamboj, KR Bainey, R Goeree, P Oh, ... ClinicoEconomics and Outcomes Research, 49-62, 2014 | 27 | 2014 |
| Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis DT Grima, A Papaioannou, MF Thompson, MK Pasquale, JD Adachi Osteoporosis international 19, 687-697, 2008 | 27 | 2008 |
| Short-term cost-effectiveness of bisphosphonate therapies for postmenopausal osteoporotic women at high risk of fracture DT Grima, RT Burge, DL Becker, ANA Tosteson P AND T 27 (9), 448-455, 2002 | 27 | 2002 |
